# Clinical Trial on Agitation in Alzheimer's Dementia

> **NCT05543681** · PHASE2 · RECRUITING · sponsor: **IGC Pharma, LLC** · enrollment: 164 (estimated)

## Conditions studied

- Alzheimer Disease
- Agitation,Psychomotor
- Care Giving Burden
- NPS
- Aggression

## Interventions

- **DRUG:** IGC-AD1-Active
- **DRUG:** IGC-AD1-Placebo

## Key facts

- **NCT ID:** NCT05543681
- **Lead sponsor:** IGC Pharma, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-11
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05543681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05543681, "Clinical Trial on Agitation in Alzheimer's Dementia". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05543681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*